Actionable news
0
All posts from Actionable news
Actionable news in IBB: iShares NASDAQ Biotechnology Index Fund,

BioDelivery Sciences Announces the Securing of Preferred Formulary Status for BUNAVAIL on a Significant Managed Care Plan

RALEIGH, N.C., July 11, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) announced it has signed an agreement with a significant managed care provider providing preferred access to BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) for the maintenance treatment of opioid dependence.

As a result of the agreement, access to BUNAVAIL will be improved substantially from its current non-formulary position with this managed care plan to a preferred formulary position, while the current market leader is made non-preferred. The other branded buprenorphine/naloxone product will share preferred status with BUNAVAIL.

While details have not been disclosed, the agreement provides access to patients with Commercial, Managed Medicaid and Medicare coverage within the plan. In total, the managed care plan that BDSI has contracted with covers in excess of 10.5 million lives and has provided coverage for an estimated more than 140,000 prescriptions over the last 12 months for buprenorphine products for opioid dependence for which the market leader has a majority, according to data from Symphony Health. The agreement officially goes into effect on January 1, 2017, although BDSI anticipates that healthcare providers may begin to make the transition prior to that date.

"During 2016, our stated strategy for BUNAVAIL has been to streamline our commercial efforts to ease our cash burn and create efficiencies, while at the same time seeking additional managed care contracts to increase the availability of BUNAVAIL nationally, all with a view towards making our BUNAVAIL operations profitable as early as possible. We are very pleased with our continued progress in both of these critical endeavors, and we believe this most recent agreement could have a significant impact on future BUNAVAIL prescription sales given the number of lives covered by this plan and the overall volume of prescriptions for buprenorphine products for opioid dependence," said Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI. "We look forward to the successful implementation of the agreement and the opportunity to transition a large portion of these patients to BUNAVAIL. In the meantime, we also continue to pursue other promising potential opportunities as payers become increasingly interested in the benefits of BUNAVAIL."

About BUNAVAIL

INDICATION

BUNAVAIL (buprenorphine and naloxone) Buccal Film (CIII) is a prescription medicine indicated for the maintenance treatment of opioid dependence. BUNAVAIL should be used as part of a complete treatment plan that includes counseling and psychosocial support.

Prescription use of this product is limited under the Drug Addiction Treatment Act (DATA).

IMPORTANT SAFETY INFORMATION

Keep BUNAVAIL (buprenorphine and naloxone) Buccal Film (CIII) out of the sight and reach of children. Ingestion of BUNAVAIL by a child may cause severe breathing problems and death. If a child takes BUNAVAIL, get emergency help right away.

Do not take BUNAVAIL if you are allergic to buprenorphine or naloxone, as serious negative effects, including anaphylactic shock, have been reported.

Do not take BUNAVAIL before the effects of other opioids (e.g., heroin, methadone, oxycodone, morphine) have lessened as you may experience withdrawal symptoms.

Do not drive, operate heavy machinery, or...


More